Pasithea Therapeutics Corp. (KTTA) company profile
Close on Nov 18, 2026Market cap $17.07MP/E –Yield –
About Pasithea Therapeutics
Pharmaceutical Preparations, SIC 2834
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company engaged in discovering, researching, and developing therapeutic treatments. Its drug development pipeline primarily focuses on small molecule therapies for RASopathies, tumors driven by the MAPK pathway, and central nervous system disorders. The company's lead therapeutic product candidate is PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor being evaluated for advanced solid tumors and neurofibromatosis type 1, including plexiform neurofibromas. Additionally, the company conducts early-stage research on its PAS-001 program, which targets complement component 4A for schizophrenia.
As a clinical-stage development enterprise, the company does not operate commercial sales facilities and aims to develop treatments for patients with high unmet medical needs. Clinical trials for its lead drug candidate take place across multiple international locations, including study sites in the United States, Eastern Europe, Australia, and South Korea. Pasithea Therapeutics Corp. is incorporated in Delaware and maintains its principal executive offices in Miami Beach, Florida.
Summary of the business section of Pasithea Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pasithea Therapeutics Corp.
- Headquarters
- Miami Beach, FL
- Address
- 1111 Lincoln Road, Suite 500 33139
- Phone
- (702) 514-4174
- Website
- pasithea.com
- Employees
- 5, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Hartford, Connecticut
Stock & identifiers
- Ticker
- KTTA
- Exchange
- Nasdaq
- IPO date
- Sep 16, 2021
- Shares outstanding
- 33M, Aug 12, 2026
- Public float
- $5.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Jan 2, 2024
- SEC CIK
- 1841330
- CUSIP
- 70261F202
- ISIN
- US70261F2020
- FIGI
- BBG01018ZGY8
- Share class FIGI
- BBG01018ZHS3
- EIN
- 85-1591963
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tiago Marques | Chief Executive Officer, Director | 73,334 |
| Kartik Krishnan | Chief Medical Officer | – |
| Daniel H. Schneiderman | Chief Financial Officer | 26,667 |
| Simon Dumesnil | Director | 35,833 |
| Lawrence Steinman | Director | 199,691 |
| Alfred J. Novak | Director | 3,500 |
| Emer Leahy | Director | 33,333 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Tiago Reis Marques Chief Executive Officer | $533.61K | $493.15K | $277.26K | $23.50K | $1.33M | +107% |
| Daniel Schneiderman Chief Financial Officer | $386.98K | $306.40K | $178.30K | $23.50K | $895.19K | +108% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 16, 2021
- Offer price
- $5.00
- Securities offered
- 4,800,000
- Gross proceeds
- $24.00M
- Exchange
- Nasdaq
- First trading day
- Sep 15, 2021
- First-day close
- $3.56-28.8%
- Lock-up ends (est.)
- Mar 14, 2022
“The initial public offering price of our Unit is $5.00 per Unit.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had five full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?